TY  - CONF
AU  - Milijić Petrović, Valentina
AU  - Marković, Mirjana
AU  - Pavlović, Dragana
AU  - Buha-Đorđević, Aleksandra
AU  - Popović, Ivana
AU  - Anđelković, Jasna
AU  - Stojkov, Svetlana
AU  - Gigov, Slobodan
AU  - Drenić, Dušan
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4553
AB  - Exact number of masters of pharmacy, level of their education, and jobs they are
engaged in is not known in Serbia. The number of pharmacists employed in health
institutions in Serbia is known (data is regularly updated by Pharmaceutical Chamber of
Serbia (FCC) because pharmacists must be licensed and registered). According to the FCC, in
Serbia, there are 6,814 Masters of Pharmacy licensed to work in healthcare institutions (1).
However, their arrangement and number by pharmacy, type and level of services are
unknown. Although all health institutions are now obliged to register through Business
Registers Agency (2), actual number of pharmacies and number of responsible pharmacists
per pharmacy remained invisible. The big question is whether all masters of pharmacy are
aware of their legal obligations, responsibilities, and professional opportunities. The number
of masters of pharmacy employed in other sectors is completely unknown. There is no
register of colleagues with completed health and academic specializations, master and
doctoral studies. The legal opportunity to acquire title of subspecialist in pharmacy should
be used and enable further training and recognition of work to colleagues who deal with
narrowly specialized pharmaceutical jobs. Funds for creating database of pharmacists (who
they are, what positions they hold, and what their level of education is) are minimal. It is only
necessary to recognize the importance of such database and connect key stakeholders. The
intersection of current situation would enable development and improvement of
pharmaceutical profession and would be step forward towards modernization of Serbian
health care system.
AB  - U Srbiji nije poznat precizan broj magistara farmacije, stepen njihovog
poslediplomskog obrazovanja i radna mesta na kojima su angažovani. Broj farmaceuta
zaposlenih u zdravstvenim ustanovama u Srbiji je poznat (podatke redovno ažurira
Farmaceutska komora Srbije (FKS), jer farmaceuti moraju imati licencu i moraju biti upisani
u FKS). Prema podacima FKS u Srbiji 6.814 magistara farmacije poseduje licencu za rad u
zdravstvenim ustanovama (1). Ipak, njihov raspored i broj po apotekama, vrsta i nivoi
njihovih usluga su nepoznati. Nakon promene zakonske regulative, sada sve zdavstvene
ustanove imaju obavezu da se registruju preko Agencije za privredne registre (2), i dalje je
ostao nevidljiv stvaran broj apoteka i odgovornih farmaceuta po svakoj apoteci. Veliko je
pitanje i da li su svi magistri farmacije svesni svojih zakonskih obaveza, odgovornosti i
profesionalnih mogućnosti. Broj magistara farmacije zaposlenih u ostalim sektorima je
potpuno nepoznat. Ne postoji ni registar kolega sa završenim zdravstvenim i akademskim
specijalizacijama, magistarskim i doktorskim studijama. Zakonsku mogućnost za sticanje
zvanja subspecijalista u farmaciji treba iskoristiti i omogućiti dalje usavršavanje i
priznavanje rada kolegama koji se bave uskostručnim farmaceutskim poslovima (npr.
onkološka farmacija). Sredstva za izradu baze farmaceuta (ko su, na kojim pozicijama rade i
kog su nivoa obrazovanja) su minimalna, a ljudski resursi već postoje. Potrebno je samo
prepoznati važnost ovakve baze i povezati ključne zainteresovane strane (FKS, Privrednu
komoru Srbije, akademiju, Savez farmaceutskih udruženja Srbije, farmaceutsku industriju).
Presek zatečenog stanja putem baze farmaceuta bi omogućio dalji razvoj i unapređenje
farmaceutske struke, i bio bi korak napred ka modernizaciji zdravstvenog sistema Srbije.
PB  - Savez farmaceutskih udruženja Srbije (SFUS)
C3  - Arhiv za farmaciju
T1  - Why do we need a pharmacist database and a reminder of the pharmacist’s job description?
T1  - Zašto nam je potrebna baza farmaceuta i podsećanje na opis poslova magistra farmacije?
VL  - 72
IS  - 4 suplement
SP  - S345
EP  - S346
UR  - https://hdl.handle.net/21.15107/rcub_farfar_4553
ER  - 

@conference{
author = "Milijić Petrović, Valentina and Marković, Mirjana and Pavlović, Dragana and Buha-Đorđević, Aleksandra and Popović, Ivana and Anđelković, Jasna and Stojkov, Svetlana and Gigov, Slobodan and Drenić, Dušan",
year = "2022",
abstract = "Exact number of masters of pharmacy, level of their education, and jobs they are
engaged in is not known in Serbia. The number of pharmacists employed in health
institutions in Serbia is known (data is regularly updated by Pharmaceutical Chamber of
Serbia (FCC) because pharmacists must be licensed and registered). According to the FCC, in
Serbia, there are 6,814 Masters of Pharmacy licensed to work in healthcare institutions (1).
However, their arrangement and number by pharmacy, type and level of services are
unknown. Although all health institutions are now obliged to register through Business
Registers Agency (2), actual number of pharmacies and number of responsible pharmacists
per pharmacy remained invisible. The big question is whether all masters of pharmacy are
aware of their legal obligations, responsibilities, and professional opportunities. The number
of masters of pharmacy employed in other sectors is completely unknown. There is no
register of colleagues with completed health and academic specializations, master and
doctoral studies. The legal opportunity to acquire title of subspecialist in pharmacy should
be used and enable further training and recognition of work to colleagues who deal with
narrowly specialized pharmaceutical jobs. Funds for creating database of pharmacists (who
they are, what positions they hold, and what their level of education is) are minimal. It is only
necessary to recognize the importance of such database and connect key stakeholders. The
intersection of current situation would enable development and improvement of
pharmaceutical profession and would be step forward towards modernization of Serbian
health care system., U Srbiji nije poznat precizan broj magistara farmacije, stepen njihovog
poslediplomskog obrazovanja i radna mesta na kojima su angažovani. Broj farmaceuta
zaposlenih u zdravstvenim ustanovama u Srbiji je poznat (podatke redovno ažurira
Farmaceutska komora Srbije (FKS), jer farmaceuti moraju imati licencu i moraju biti upisani
u FKS). Prema podacima FKS u Srbiji 6.814 magistara farmacije poseduje licencu za rad u
zdravstvenim ustanovama (1). Ipak, njihov raspored i broj po apotekama, vrsta i nivoi
njihovih usluga su nepoznati. Nakon promene zakonske regulative, sada sve zdavstvene
ustanove imaju obavezu da se registruju preko Agencije za privredne registre (2), i dalje je
ostao nevidljiv stvaran broj apoteka i odgovornih farmaceuta po svakoj apoteci. Veliko je
pitanje i da li su svi magistri farmacije svesni svojih zakonskih obaveza, odgovornosti i
profesionalnih mogućnosti. Broj magistara farmacije zaposlenih u ostalim sektorima je
potpuno nepoznat. Ne postoji ni registar kolega sa završenim zdravstvenim i akademskim
specijalizacijama, magistarskim i doktorskim studijama. Zakonsku mogućnost za sticanje
zvanja subspecijalista u farmaciji treba iskoristiti i omogućiti dalje usavršavanje i
priznavanje rada kolegama koji se bave uskostručnim farmaceutskim poslovima (npr.
onkološka farmacija). Sredstva za izradu baze farmaceuta (ko su, na kojim pozicijama rade i
kog su nivoa obrazovanja) su minimalna, a ljudski resursi već postoje. Potrebno je samo
prepoznati važnost ovakve baze i povezati ključne zainteresovane strane (FKS, Privrednu
komoru Srbije, akademiju, Savez farmaceutskih udruženja Srbije, farmaceutsku industriju).
Presek zatečenog stanja putem baze farmaceuta bi omogućio dalji razvoj i unapređenje
farmaceutske struke, i bio bi korak napred ka modernizaciji zdravstvenog sistema Srbije.",
publisher = "Savez farmaceutskih udruženja Srbije (SFUS)",
journal = "Arhiv za farmaciju",
title = "Why do we need a pharmacist database and a reminder of the pharmacist’s job description?, Zašto nam je potrebna baza farmaceuta i podsećanje na opis poslova magistra farmacije?",
volume = "72",
number = "4 suplement",
pages = "S345-S346",
url = "https://hdl.handle.net/21.15107/rcub_farfar_4553"
}

Milijić Petrović, V., Marković, M., Pavlović, D., Buha-Đorđević, A., Popović, I., Anđelković, J., Stojkov, S., Gigov, S.,& Drenić, D.. (2022). Why do we need a pharmacist database and a reminder of the pharmacist’s job description?. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije (SFUS)., 72(4 suplement), S345-S346.
https://hdl.handle.net/21.15107/rcub_farfar_4553

Milijić Petrović V, Marković M, Pavlović D, Buha-Đorđević A, Popović I, Anđelković J, Stojkov S, Gigov S, Drenić D. Why do we need a pharmacist database and a reminder of the pharmacist’s job description?. in Arhiv za farmaciju. 2022;72(4 suplement):S345-S346.
https://hdl.handle.net/21.15107/rcub_farfar_4553 .

Milijić Petrović, Valentina, Marković, Mirjana, Pavlović, Dragana, Buha-Đorđević, Aleksandra, Popović, Ivana, Anđelković, Jasna, Stojkov, Svetlana, Gigov, Slobodan, Drenić, Dušan, "Why do we need a pharmacist database and a reminder of the pharmacist’s job description?" in Arhiv za farmaciju, 72, no. 4 suplement (2022):S345-S346,
https://hdl.handle.net/21.15107/rcub_farfar_4553 .

TY  - CONF
AU  - Anđelković, Jasna
AU  - Milijić Petrović, Valentina
AU  - Marković, Mirjana
AU  - Pavlović, Dragana
AU  - Buha-Đorđević, Aleksandra
AU  - Popović, Ivana
AU  - Stojkov, Svetlana
AU  - Gigov, Slobodan
AU  - Drenić, Dušan
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4528
AB  - This paper presents a set of recommendations that can contribute to the improvement
of the pharmacy business. They resulted from a series of professional meetings and a
collection of opinions from masters of pharmacy employed in various health care institutions
in the Republic of Serbia. The general recommendation would imply strict compliance with
existing laws (Law on Medicines and Medical Devices (1), Law on Health Care (2)), but also
the adoption of the Law on Pharmacy, following the example of countries with developed
pharmacy practice. Individual key provisions that would bring improvement of pharmacy
and quality pharmaceutical services to patients in the short term are the mandatory
presence of at least one licensed pharmacist during the entire working hours in each
pharmacy, as well as compliance and control of prescription and over-the-counter medicines.
In the long term, strengthening national regulatory bodies in the field of medicines and
medical devices is important for improving the quality, safety, and efficacy of medicines and
the issuance and application of therapy. According to all standards, these jobs should be
entrusted exclusively to masters of pharmacy, and in certain cases to appropriate pharmacy
specialists. Development of specific clinical skills and introduction of additional services,
such as vaccination and disposal of pharmaceutical waste, would significantly contribute to
resource savings and contribute to the health system.
AB  - Ovaj rad predstavlja skup preporuka koje mogu doprineti poboljšanju apotekarske
delatnosti, a koje su proistekle iz niza stručnih sastanaka i prikupljanja mišljenja od
magistara farmacije zaposlenih u različitim zdravstvenim ustanovama u Republici Srbiji.
Opšta preporuka bi podrazumevala strogo poštovanje postojećih zakona (Zakona o lekovima
i medicinskim sredstavima (1), Zakon o zdravstvenoj zaštiti (2)), ali i donošenje Zakona o
apotekarskoj delatnosti, po ugledu na države sa razvijenom apotekarskom praksom.
Pojedinačne ključne odredbe koje bi u kratkom vremenskom roku donele unapređenje
apotekarske delatnosti i kvalitetne farmaceutske usluge ka pacijentima su obavezno
prisustvo najmanje jednog diplomiranog farmaceuta sa licencom tokom celokupnog radnog
vremena u svakoj apoteci, kao i poštovanje i kontrola režima izdavanja lekova na recept i
lekova bez recepta. Na dugi rok, jačanje nacionalnih regulatornih tela u oblasti lekova i
medicinskih sredstava je značajno radi poboljšanja kvaliteta, bezbednosti i efikasnosti lekova
i izdavanja i primene terapije. Ovi poslovi bi prema svim standardima morali biti povereni
isključivo magistrima farmacije, a u određenim slučajevima i odgovarajućim specijalistima
farmacije. Razvoj specifičnih kliničkih veština i uvođenje dodatnih usluga, kao što su npr.
vakcinacija i zbrinjavanje farmaceutskog otpada, bi značajno doprineli uštedama resursa i
doprineli zdravstvenom sistemu u celini.
PB  - Savez farmaceutskih udruženja Srbije (SFUS)
C3  - Arhiv za farmaciju
T1  - Development of pharmacy activity in Serbia - what do we need?
T1  - Razvoj apotekarske delatnosti u srbiji‐ šta nam je potrebno?
VL  - 72
IS  - 4 suplement
SP  - S284
EP  - S285
UR  - https://hdl.handle.net/21.15107/rcub_farfar_4528
ER  - 

@conference{
author = "Anđelković, Jasna and Milijić Petrović, Valentina and Marković, Mirjana and Pavlović, Dragana and Buha-Đorđević, Aleksandra and Popović, Ivana and Stojkov, Svetlana and Gigov, Slobodan and Drenić, Dušan",
year = "2022",
abstract = "This paper presents a set of recommendations that can contribute to the improvement
of the pharmacy business. They resulted from a series of professional meetings and a
collection of opinions from masters of pharmacy employed in various health care institutions
in the Republic of Serbia. The general recommendation would imply strict compliance with
existing laws (Law on Medicines and Medical Devices (1), Law on Health Care (2)), but also
the adoption of the Law on Pharmacy, following the example of countries with developed
pharmacy practice. Individual key provisions that would bring improvement of pharmacy
and quality pharmaceutical services to patients in the short term are the mandatory
presence of at least one licensed pharmacist during the entire working hours in each
pharmacy, as well as compliance and control of prescription and over-the-counter medicines.
In the long term, strengthening national regulatory bodies in the field of medicines and
medical devices is important for improving the quality, safety, and efficacy of medicines and
the issuance and application of therapy. According to all standards, these jobs should be
entrusted exclusively to masters of pharmacy, and in certain cases to appropriate pharmacy
specialists. Development of specific clinical skills and introduction of additional services,
such as vaccination and disposal of pharmaceutical waste, would significantly contribute to
resource savings and contribute to the health system., Ovaj rad predstavlja skup preporuka koje mogu doprineti poboljšanju apotekarske
delatnosti, a koje su proistekle iz niza stručnih sastanaka i prikupljanja mišljenja od
magistara farmacije zaposlenih u različitim zdravstvenim ustanovama u Republici Srbiji.
Opšta preporuka bi podrazumevala strogo poštovanje postojećih zakona (Zakona o lekovima
i medicinskim sredstavima (1), Zakon o zdravstvenoj zaštiti (2)), ali i donošenje Zakona o
apotekarskoj delatnosti, po ugledu na države sa razvijenom apotekarskom praksom.
Pojedinačne ključne odredbe koje bi u kratkom vremenskom roku donele unapređenje
apotekarske delatnosti i kvalitetne farmaceutske usluge ka pacijentima su obavezno
prisustvo najmanje jednog diplomiranog farmaceuta sa licencom tokom celokupnog radnog
vremena u svakoj apoteci, kao i poštovanje i kontrola režima izdavanja lekova na recept i
lekova bez recepta. Na dugi rok, jačanje nacionalnih regulatornih tela u oblasti lekova i
medicinskih sredstava je značajno radi poboljšanja kvaliteta, bezbednosti i efikasnosti lekova
i izdavanja i primene terapije. Ovi poslovi bi prema svim standardima morali biti povereni
isključivo magistrima farmacije, a u određenim slučajevima i odgovarajućim specijalistima
farmacije. Razvoj specifičnih kliničkih veština i uvođenje dodatnih usluga, kao što su npr.
vakcinacija i zbrinjavanje farmaceutskog otpada, bi značajno doprineli uštedama resursa i
doprineli zdravstvenom sistemu u celini.",
publisher = "Savez farmaceutskih udruženja Srbije (SFUS)",
journal = "Arhiv za farmaciju",
title = "Development of pharmacy activity in Serbia - what do we need?, Razvoj apotekarske delatnosti u srbiji‐ šta nam je potrebno?",
volume = "72",
number = "4 suplement",
pages = "S284-S285",
url = "https://hdl.handle.net/21.15107/rcub_farfar_4528"
}

Anđelković, J., Milijić Petrović, V., Marković, M., Pavlović, D., Buha-Đorđević, A., Popović, I., Stojkov, S., Gigov, S.,& Drenić, D.. (2022). Development of pharmacy activity in Serbia - what do we need?. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije (SFUS)., 72(4 suplement), S284-S285.
https://hdl.handle.net/21.15107/rcub_farfar_4528

Anđelković J, Milijić Petrović V, Marković M, Pavlović D, Buha-Đorđević A, Popović I, Stojkov S, Gigov S, Drenić D. Development of pharmacy activity in Serbia - what do we need?. in Arhiv za farmaciju. 2022;72(4 suplement):S284-S285.
https://hdl.handle.net/21.15107/rcub_farfar_4528 .

Anđelković, Jasna, Milijić Petrović, Valentina, Marković, Mirjana, Pavlović, Dragana, Buha-Đorđević, Aleksandra, Popović, Ivana, Stojkov, Svetlana, Gigov, Slobodan, Drenić, Dušan, "Development of pharmacy activity in Serbia - what do we need?" in Arhiv za farmaciju, 72, no. 4 suplement (2022):S284-S285,
https://hdl.handle.net/21.15107/rcub_farfar_4528 .

TY  - JOUR
AU  - Marković, Mirjana
AU  - Ignjatović, Svetlana
AU  - Dajak, Marijana
AU  - Majkić-Singh, Nada
PY  - 2010
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1412
AB  - Background: Placental growth factor (PlGF) belongs to the vascular endothelial growth factor family and seems to be an independent biomarker for plaque disruption, ischemia, and thrombosis. Plasma PlGF is rapidly produced in infarcted myocardial tissue during the acute phase of myocardial infarction. In this study, the relevance of PIGF was analyzed at the admission of patients with acute coronary syndrome (ACS) without ST elevation for the prognosis of fatal outcome after 30 days. Methods: We collected blood samples from 102 ACS patients admitted to the coronary unit with manifesting acute chest pain within the previous 12 hours and measured the levels of PIGF, high-sensitivity C-reactive protein (hsCRP), and cardiac markers: troponin T (cTnT), B-type natriuretic peptide, creatine kinase-MB (CKMB) and CK activity. Results: PlGF, troponin T, and hsCRP levels were significantly higher in non-survivors than in survivors. ROC analysis showed that PIGF had the highest area under ROC curve (AUC, 0.713), but it was not significantly different from AUCs for cTnT and hsCRP. Higher values of PlGF (>13.2 ng/L) pointed towards a higher risk of fatal outcome (HR 2.28; 95 % CI 1.21-4.76; P=0.0125). The multivariable proportional hazards analysis, which had involved other statistically significant markers of relative risk (age and gender), showed that PlGF was an independent prognostic marker (adjusted HR 2.14; 95 % CI 1.08-4.22). Conclusions: These results confirmed that PlGF is an independent biomarker of short-term adverse outcome in patients with ACS without ST elevation and that plaque instability, represented by PlGF elevation, has an important role in the pathogenesis of future coronary events. (Clin. Lab. 2010;56:215-222)
PB  - Clin Lab Publ, Heidelberg
T2  - Clinical Laboratory
T1  - Utility of Placental Growth Factor for Prediction of 30-Day Adverse Event in Emergency Department Population with Non-ST Elevation Acute Coronary Syndrome
VL  - 56
IS  - 5-6
SP  - 215
EP  - 222
UR  - https://hdl.handle.net/21.15107/rcub_farfar_1412
ER  - 

@article{
author = "Marković, Mirjana and Ignjatović, Svetlana and Dajak, Marijana and Majkić-Singh, Nada",
year = "2010",
abstract = "Background: Placental growth factor (PlGF) belongs to the vascular endothelial growth factor family and seems to be an independent biomarker for plaque disruption, ischemia, and thrombosis. Plasma PlGF is rapidly produced in infarcted myocardial tissue during the acute phase of myocardial infarction. In this study, the relevance of PIGF was analyzed at the admission of patients with acute coronary syndrome (ACS) without ST elevation for the prognosis of fatal outcome after 30 days. Methods: We collected blood samples from 102 ACS patients admitted to the coronary unit with manifesting acute chest pain within the previous 12 hours and measured the levels of PIGF, high-sensitivity C-reactive protein (hsCRP), and cardiac markers: troponin T (cTnT), B-type natriuretic peptide, creatine kinase-MB (CKMB) and CK activity. Results: PlGF, troponin T, and hsCRP levels were significantly higher in non-survivors than in survivors. ROC analysis showed that PIGF had the highest area under ROC curve (AUC, 0.713), but it was not significantly different from AUCs for cTnT and hsCRP. Higher values of PlGF (>13.2 ng/L) pointed towards a higher risk of fatal outcome (HR 2.28; 95 % CI 1.21-4.76; P=0.0125). The multivariable proportional hazards analysis, which had involved other statistically significant markers of relative risk (age and gender), showed that PlGF was an independent prognostic marker (adjusted HR 2.14; 95 % CI 1.08-4.22). Conclusions: These results confirmed that PlGF is an independent biomarker of short-term adverse outcome in patients with ACS without ST elevation and that plaque instability, represented by PlGF elevation, has an important role in the pathogenesis of future coronary events. (Clin. Lab. 2010;56:215-222)",
publisher = "Clin Lab Publ, Heidelberg",
journal = "Clinical Laboratory",
title = "Utility of Placental Growth Factor for Prediction of 30-Day Adverse Event in Emergency Department Population with Non-ST Elevation Acute Coronary Syndrome",
volume = "56",
number = "5-6",
pages = "215-222",
url = "https://hdl.handle.net/21.15107/rcub_farfar_1412"
}

Marković, M., Ignjatović, S., Dajak, M.,& Majkić-Singh, N.. (2010). Utility of Placental Growth Factor for Prediction of 30-Day Adverse Event in Emergency Department Population with Non-ST Elevation Acute Coronary Syndrome. in Clinical Laboratory
Clin Lab Publ, Heidelberg., 56(5-6), 215-222.
https://hdl.handle.net/21.15107/rcub_farfar_1412

Marković M, Ignjatović S, Dajak M, Majkić-Singh N. Utility of Placental Growth Factor for Prediction of 30-Day Adverse Event in Emergency Department Population with Non-ST Elevation Acute Coronary Syndrome. in Clinical Laboratory. 2010;56(5-6):215-222.
https://hdl.handle.net/21.15107/rcub_farfar_1412 .

Marković, Mirjana, Ignjatović, Svetlana, Dajak, Marijana, Majkić-Singh, Nada, "Utility of Placental Growth Factor for Prediction of 30-Day Adverse Event in Emergency Department Population with Non-ST Elevation Acute Coronary Syndrome" in Clinical Laboratory, 56, no. 5-6 (2010):215-222,
https://hdl.handle.net/21.15107/rcub_farfar_1412 .

TY  - JOUR
AU  - Marković, Mirjana
AU  - Ignjatović, Svetlana
AU  - Dajak, Marijana
AU  - Majkić-Singh, Nada
PY  - 2010
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1362
AB  - Objectives: The relevance of placental growth factor was analyzed at the admission of patients with acute coronary syndrome (ACS) without ST elevation in prognosis of fatal outcome after 30 days. Methods: We collected blood samples from 102 ACS patients admitted to the coronary unit with acute chest pain manifesting within the last 12 hours. Results: In all 102 admitted patients, higher values of placental growth factor (PLGF; >13.2 ng/L, average value) indicated a higher risk of fatal outcome (hazard ratio [HR] 2.28, 95% confidence interval [CI] 1.21-4.76, P = 0.0125). PLGF is an important independent prognostic marker (adjusted HR 2.35, 95% CI 1.98-4.61, P = 0.1338), and this was shown in a multiparameter model, which involved other statistically important markers of relative risk (age >65, gender, and estimated glomerular filtration rate [eGFR]). Conclusion: PLGF levels measured at 12 hours of symptom onset and 30 days later may independently predict fatal outcome in patients with ACS without ST elevation.
PB  - Lippincott Williams & Wilkins, Philadelphia
T2  - Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy
T1  - Placental Growth Factor as Short-Term Predicting Biomarker in Acute Coronary Syndrome Patients with Non-ST Elevation Myocardial Infarction
VL  - 103
IS  - 10
SP  - 982
EP  - 987
DO  - 10.1097/SMJ.0b013e3181eda4ef
ER  - 

@article{
author = "Marković, Mirjana and Ignjatović, Svetlana and Dajak, Marijana and Majkić-Singh, Nada",
year = "2010",
abstract = "Objectives: The relevance of placental growth factor was analyzed at the admission of patients with acute coronary syndrome (ACS) without ST elevation in prognosis of fatal outcome after 30 days. Methods: We collected blood samples from 102 ACS patients admitted to the coronary unit with acute chest pain manifesting within the last 12 hours. Results: In all 102 admitted patients, higher values of placental growth factor (PLGF; >13.2 ng/L, average value) indicated a higher risk of fatal outcome (hazard ratio [HR] 2.28, 95% confidence interval [CI] 1.21-4.76, P = 0.0125). PLGF is an important independent prognostic marker (adjusted HR 2.35, 95% CI 1.98-4.61, P = 0.1338), and this was shown in a multiparameter model, which involved other statistically important markers of relative risk (age >65, gender, and estimated glomerular filtration rate [eGFR]). Conclusion: PLGF levels measured at 12 hours of symptom onset and 30 days later may independently predict fatal outcome in patients with ACS without ST elevation.",
publisher = "Lippincott Williams & Wilkins, Philadelphia",
journal = "Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy",
title = "Placental Growth Factor as Short-Term Predicting Biomarker in Acute Coronary Syndrome Patients with Non-ST Elevation Myocardial Infarction",
volume = "103",
number = "10",
pages = "982-987",
doi = "10.1097/SMJ.0b013e3181eda4ef"
}

Marković, M., Ignjatović, S., Dajak, M.,& Majkić-Singh, N.. (2010). Placental Growth Factor as Short-Term Predicting Biomarker in Acute Coronary Syndrome Patients with Non-ST Elevation Myocardial Infarction. in Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy
Lippincott Williams & Wilkins, Philadelphia., 103(10), 982-987.
https://doi.org/10.1097/SMJ.0b013e3181eda4ef

Marković M, Ignjatović S, Dajak M, Majkić-Singh N. Placental Growth Factor as Short-Term Predicting Biomarker in Acute Coronary Syndrome Patients with Non-ST Elevation Myocardial Infarction. in Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy. 2010;103(10):982-987.
doi:10.1097/SMJ.0b013e3181eda4ef .

Marković, Mirjana, Ignjatović, Svetlana, Dajak, Marijana, Majkić-Singh, Nada, "Placental Growth Factor as Short-Term Predicting Biomarker in Acute Coronary Syndrome Patients with Non-ST Elevation Myocardial Infarction" in Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy, 103, no. 10 (2010):982-987,
https://doi.org/10.1097/SMJ.0b013e3181eda4ef . .

TY  - JOUR
AU  - Marković, Mirjana
AU  - Ignjatović, Svetlana
AU  - Majkić-Singh, Nada
AU  - Dajak, Marijana
PY  - 2009
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1165
AB  - Background: Markers of plaque instability are considered as predictors of future events in patients with non ST-elevation myocardial infarction (NSTEMI) in acute coronary syndrome (ACS). The aim of this was to determine the role of placental growth factor (PIGF) as a possible: predictor of future coronary events such as non-fatal myocardial infarction or cardiac death measured at the admission and 30 days, after discharge. Methods: We prospectively collected data from 102 patients admitted to the emergency department (ED) for ACS with chest pain at rest within the preceding 12 hours who were evaluated by risk factors and electrocardiogram changes (ECG). Results: The time course of PIGF levels. determined on 102 patients showed a mean. value 13.21 ng/L and standard deviation 8.76 ng/L but in the sample of the 53 patients who survived after 30 days, these values decreased to 10.48 ng/L and 5.45 ng/L, respectively, Conclusions: Results of this study indicate a clinically useful role of PIGF in the detection of ACS and NSTEMI patients who are at a higher risk for different cardiovascular disorders within 30 days of admission.
PB  - Amer Soc Clinical Pathology, Chicago
T2  - Labmedicine
T1  - Placental Growth Factor in Acute Coronary Syndrome Patients with Non ST-Elevation
VL  - 40
IS  - 11
SP  - 675
EP  - 678
DO  - 10.1309/LMK6X47RSYRCGCSB
ER  - 

@article{
author = "Marković, Mirjana and Ignjatović, Svetlana and Majkić-Singh, Nada and Dajak, Marijana",
year = "2009",
abstract = "Background: Markers of plaque instability are considered as predictors of future events in patients with non ST-elevation myocardial infarction (NSTEMI) in acute coronary syndrome (ACS). The aim of this was to determine the role of placental growth factor (PIGF) as a possible: predictor of future coronary events such as non-fatal myocardial infarction or cardiac death measured at the admission and 30 days, after discharge. Methods: We prospectively collected data from 102 patients admitted to the emergency department (ED) for ACS with chest pain at rest within the preceding 12 hours who were evaluated by risk factors and electrocardiogram changes (ECG). Results: The time course of PIGF levels. determined on 102 patients showed a mean. value 13.21 ng/L and standard deviation 8.76 ng/L but in the sample of the 53 patients who survived after 30 days, these values decreased to 10.48 ng/L and 5.45 ng/L, respectively, Conclusions: Results of this study indicate a clinically useful role of PIGF in the detection of ACS and NSTEMI patients who are at a higher risk for different cardiovascular disorders within 30 days of admission.",
publisher = "Amer Soc Clinical Pathology, Chicago",
journal = "Labmedicine",
title = "Placental Growth Factor in Acute Coronary Syndrome Patients with Non ST-Elevation",
volume = "40",
number = "11",
pages = "675-678",
doi = "10.1309/LMK6X47RSYRCGCSB"
}

Marković, M., Ignjatović, S., Majkić-Singh, N.,& Dajak, M.. (2009). Placental Growth Factor in Acute Coronary Syndrome Patients with Non ST-Elevation. in Labmedicine
Amer Soc Clinical Pathology, Chicago., 40(11), 675-678.
https://doi.org/10.1309/LMK6X47RSYRCGCSB

Marković M, Ignjatović S, Majkić-Singh N, Dajak M. Placental Growth Factor in Acute Coronary Syndrome Patients with Non ST-Elevation. in Labmedicine. 2009;40(11):675-678.
doi:10.1309/LMK6X47RSYRCGCSB .

Marković, Mirjana, Ignjatović, Svetlana, Majkić-Singh, Nada, Dajak, Marijana, "Placental Growth Factor in Acute Coronary Syndrome Patients with Non ST-Elevation" in Labmedicine, 40, no. 11 (2009):675-678,
https://doi.org/10.1309/LMK6X47RSYRCGCSB . .